Experience

Ken Rollins

    • Regulus Therapeutics: $50.9 Million Initial Public Offering 


    • Synthorx: $63 Million Series C Financing 


    • AltheaDx: $30 Million Series C Financing 


    • Auspex Pharma $3.5 billion sale to Teva Pharma 


    • Auspex Pharma Acquired by Teva for $3.5 Billion 


    • Auspex Pharma Acquired by Teva for $3.5 Billion 


    • Cooley Advises Xencor on its Initial Public Offering 


    • Auspex $96 Million Initial Public Offering 


    • Cooley Advises Auspex on its Initial Public Offering 


    • Xencor Initial Public Offering 


    • Ambit Initial Public Offering 


    • Cooley Advises Ambit on its IPO